News
Insights from the frontlines of venture
Insights from the frontlines of venture
News and milestones from 25 years in technology and healthcare.
News and milestones from 25 years in technology and healthcare.
SEP 02, 2026
Vara receives world-first CE certification for autonomous AI in breast cancer screening
Read More
Read more
AUG 27, 2026
HighLife Receives CE Mark Approval for Clarity Valve, the Next-Generation Valve for the HighLife TMVR System
Read More
Read more
JUL 30, 2026
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
Read More
Read more
JUL 7, 2026
Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
Read More
Read more
JUN 16, 2026
Why we invested in Airspeed
Read More
Read more
JUN 4, 2026
Vi Partners invests in Airspeed, marking first investment from its new CHF 150 million target fund
Read More
Read more
MAR 31, 2026
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Read More
Read more
MAR 18, 2026
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System — the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) in the United States
Read More
Read more
MAR 10, 2026
Vi Partners welcomes Julien Pache as Partner, Technology
Read More
Read more
JAN 21, 2026
Vi Partners announces first close of its new CHF 150 million fund, reinforcing its long-term commitment to Swiss innovation
Read More
Read more
DEC 05, 2025
iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new nonclinical data at ASH
Read More
Read more
DEC 03, 2025
Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market
Read More
Read more
SEP 02, 2026
Vara receives world-first CE certification for autonomous AI in breast cancer screening
Read More
Read more
AUG 27, 2026
HighLife Receives CE Mark Approval for Clarity Valve, the Next-Generation Valve for the HighLife TMVR System
Read More
Read more
JUL 30, 2026
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa
Read More
Read more
JUL 7, 2026
Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
Read More
Read more
JUN 16, 2026
Why we invested in Airspeed
Read More
Read more
JUN 4, 2026
Vi Partners invests in Airspeed, marking first investment from its new CHF 150 million target fund
Read More
Read more
MAR 31, 2026
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Read More
Read more
MAR 18, 2026
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System — the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) in the United States
Read More
Read more
MAR 10, 2026
Vi Partners welcomes Julien Pache as Partner, Technology
Read More
Read more